I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma

Seminars in Nuclear Medicine

Volumn 46, Issue 3, 2016, Pages 203-214

  Carrasquillo, Jorge A ^a,b   Pandit Taskar, Neeta ^a,b   Chen, Clara C ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 131; INDIUM 111; LUTETIUM 177; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TETRAXETAN; YTTRIUM 90;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; ASTHENIA; BLOOD TOXICITY; BRONCHIOLITIS OBLITERANS; CLINICAL EVALUATION; DOSIMETRY; DRUG ACTIVITY; DRUG DETERMINATION; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOTHYROIDISM; KIDNEY FAILURE; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; PARAGANGLIOMA; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PROTEINURIA; RADIOISOTOPE THERAPY; REVIEW; SEVERE HEPATIC IMPAIRMENT; TREATMENT RESPONSE; ADRENAL GLAND NEOPLASMS; PATHOLOGY;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA;

EID: 84962875281     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2016.01.011     Document Type: Review

References (119)

1. K. Pacak, and S.J. Wimalawansa Pheochromocytoma and paraganglioma Endocr Pract 21 4 2015 406 412
2. B.E. Baysal, J.E. Willett-Brozick, E.C. Lawrence, and et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas J Med Genet 39 3 2002 178 183
3. P.L.M. Dahia Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity Nat Rev Cancer 14 2 2014 108 119
4. 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma J Clin Endocrinol Metab 94 12 2009 4757 4767
5. H. Timmers, A. Kozupa, C.C. Chen, and et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma J Clin Oncol 25 16 2007 2262 2269
6. S. Gonias, R. Goldsby, K.K. Matthay, and et al. Phase II study of high-dose I-131 metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma J Clin Oncol 27 25 2009 4162 4168
7. M. Ayala-Ramirez, C.N. Chougnet, M.A. Habra, and et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas J Clin Endocrinol Metab 97 11 2012 4040 4050
8. S.D. Averbuch, C.S. Steakley, R.C. Young, and et al. Malignant pheochromocytoma - Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine Ann Intern Med 109 4 1988 267 273
9. J. Hadoux, J. Favier, J.Y. Scoazec, and et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma Int J Cancer 135 11 2014 2711 2720
10. M.R. Castellani, S. Seghezzi, C. Chiesa, and et al. I-131-MIBG treatment of pheochromocytoma: Low versus intermediate activity regimens of therapy Q J Nucl Med Mol Imaging 54 1 2010 100 113
11. K. Yoshinaga, N. Oriuchi, H. Wakabayashi, and et al. Effects and safety of I-131-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry Endocr J 61 12 2014 1171 1180
12. K.C. Loh, P.A. Fitzgerald, K.K. Matthay, and et al. The treatment of malignant metaiodobenzylguanidine (I-131-MIBG): A comprehensive review of 116 reported patients J Endocrinol Invest 20 11 1997 648 658
13. M. Fischer Therapy of pheochromocytoma with [131I]metaiodobenzylguanidine J Nucl Biol Med 35 4 1991 292 294
14. J.J. Mukherjee, G.A. Kaltsas, N. Islam, and et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with I-131-meta-iodobenzylguanidine (I-131-MIBG) Clin Endocrinol 55 1 2001 47 60
15. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma Eur J Nucl Med Mol Imaging 35 4 2008 725 733
16. 131IMetaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma J Nucl Biol Med 35 4 1991 288 291
17. N.D. Niemeijer, G. Alblas, L.T. van Hulsteijn, and et al. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: Systematic review and meta-analysis Clin Endocrinol 81 5 2014 642 651
18. J.C. Sisson, M.S. Frager, T.W. Valk, and et al. Scintigraphic localization of pheochromocytoma N Engl J Med 305 1 1981 12 17
19. D.M. Wieland, J.I. Wu, L.E. Brown, and et al. Radiolabeled adrenergic neuron-blocking agents - Adrenomedullary imaging with I-131 iodobenzylguanidine J Nucl Med 21 4 1980 349 353
20. J.C. Sisson, B. Shapiro, W.H. Beierwaltes, and et al. Radiopharmaceutical treatment of malignant pheochromocytoma J Nucl Med 25 2 1984 197 206
21. T.T. Huynh, K. Pacak, F.M. Brouwers, and et al. Different expression of catecholamine transporters in phaeochromocytomas from patients with Von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 Eur J Endocrinol 153 4 2005 551 563
22. L. Kolby, P. Bernhardt, A.M. Levin-Jakobsen, and et al. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters Br J Cancer 89 7 2003 1383 1388
23. A. Saveanu, M. Muresan, C. De Micco, and et al. Expression of somatostatin receptors, dopamine D-2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas Endocr Relat Cancer 18 2 2011 287 300
24. A. van Berkel, J.U. Rao, J.W.M. Lenders, and et al. Semiquantitative I-123-metaiodobenzylguanidine scintigraphy to distinguish pheochromocytoma and paraganglioma from physiologic adrenal uptake and its correlation with genotype-dependent expression of catecholamine transporters J Nucl Med 56 6 2015 839 846
25. 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: With vesicular monoamine transporter expression J Clin Endocrinol Metab 95 6 2010 2800 2810
26. J. Bomanji, D.A. Levison, W.D. Flatman, and et al. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: A histopathological comparison J Nucl Med 28 6 1987 973 978
27. A. Szalat, M. Fraenkel, V. Doviner, and et al. Malignant pheochromocytoma: Predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center Endocrine 39 2 2011 160 166
28. D.M. Wieland, L.E. Brown, M.C. Tobes, and et al. Imaging the primate adrenal-medulla with [I-123] and [I-131] metalodobenzylguanidine - Concise communication J Nucl Med 22 4 1981 358 364
29. L.A. Smets, M. Janssen, M. Rutgers, and et al. Pharmacokinetics and intracellular-distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in sk-n-sh neuroblastoma and pc-12 pheochromocytoma cells Int J Cancer 48 4 1991 609 615
30. L.S. Lashford, J.P. Hancock, and J.T. Kemshead Metaiodobenzylguanidine uptake and storage in the human neuroblastoma cell-line sk-n-be(2c) Int J Cancer 47 1 1991 105 109
31. V. Rufini, and B. Shulkin The evolution in the use of MIBG in more than 25 years of experimental and clinical applications Q J Nucl Med Mol Imaging 52 4 2008 341 350
32. J.A. Carrasquillo, and C.C. Chen Molecular imaging of neuroendocrine tumors Semin Oncol 37 6 2010 662 679
33. S. Shusterman, F.D. Grant, W. Lorenzen, and et al. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: Program planning and initial experience Semin Nucl Med 41 5 2011 354 363
34. J. de Kraker, K.A. Hoefnagel, A.C. Verschuur, and et al. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age Eur J Cancer 44 4 2008 551 556
35. S.L. Fielding, M.A. Flower, D.M. Ackery, and et al. The treatment of resistant neuroblastoma with I-131 metaiodobenzylguanidine - Alternative methods of dose prescription Radiother Oncol 25 1 1992 73 76
36. R.J. Hutchinson, J.C. Sisson, B. Shapiro, and et al. 131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma Am J Clin Oncol 15 3 1992 226 232
37. R. Mastrangelo, A. Tornesello, R. Riccardi, and et al. A new approach in the treatment of stage-IV neuroblastoma using a combination of I-131 metaiodobenzylguanidine (MIBG) and cisplatin Eur J Cancer 31A 4 1995 606 611
38. J.C. Sisson, B. Shapiro, B.L. Shulkin, and et al. Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy Am J Clin Oncol 22 4 1999 364 370
39. G. Vaidyanathan, D.J. Affleck, and M.R. Zalutsky No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue Appl Radiat Isot 62 3 2005 435 440
40. R.J. Mairs, S.H. Cunningham, J. Russell, and et al. No-carrier-added iodine-131-MIBG - Evaluation of a therapeutic preparation J Nucl Med 36 6 1995 1088 1095
41. R.J. Mairs, M.N. Gaze, D.G. Watson, and et al. Carrier-free I-131 metaiodobenzylguanidine - Comparison of production from meta-diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine Nucl Med Commun 15 4 1994 268 274
42. R.J. Mairs, J. Russell, S. Cunningham, and et al. Enhanced tumor uptake and in-vitro radiotoxicity of no-carrier-added [I-131] metaiodobenzylguanidine - Implications for the targeted radiotherapy of neuroblastoma Eur J Cancer 31A 4 1995 576 581
43. R.E. Coleman, J.B. Stubbs, J.A. Barrett, and et al. Radiation dosimetry, pharmacokinetics, and safety of ultratrace (TM) iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid Cancer Biother Radiopharm 24 4 2009 469 475
44. J.A. Barrett, J.L. Joyal, S.M. Hillier, and et al. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution Cancer Biother Radiopharm 25 3 2010 299 308
45. J. Owens, A.A. Bolster, J.E. Prosser, and et al. No-carrier-added I-123-MIBG: An initial clinical study in patients with phaeochromocytoma Nucl Med Commun 21 5 2000 437 440
46. F. Giammarile, A. Chiti, M. Lassmann, and et al. EANM procedure guidelines for I-131-meta-iodobenzylguanidine (I-131-MIBG) therapy Eur J Nucl Med Mol Imaging 35 5 2008 1039 1047
47. F.A. Khafagi, B. Shapiro, L.M. Fig, and et al. Labetalol reduces I-131 MIBG uptake by pheochromocytoma and normal-tissues J Nucl Med 30 4 1989 481 489
48. C.A. Hoefnagel, J. Schornagel, and R.A. Valdes-Olmos I-131 metaiodobenzylguanidine therapy of malignant pheochromocytoma: Interference of medication J Nucl Biol Med 35 4 1991 308 312
49. J. Morais, H. Lemarec, P. Peltier, and et al. Metaiodobenzylguanidine scintigraphy of a patient with pheochromocytoma on labetalol therapy Clin Nucl Med 17 4 1992 308 311
50. K.K. Solanki, J. Bomanji, J. Moyes, and et al. A pharmacological guide to medicines which interfere with the biodistribution of radiolabeled metaiodobenzylguanidine Nucl Med Commun 13 7 1992 513 521
51. J.W. Babich, W. Graham, and A.J. Fischman Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells Eur J Nucl Med 24 5 1997 538 543
52. G.M. Blake, V.J. Lewington, J.S. Fleming, and et al. Modification by nifedipine of I-131-meta-iodobenzylguanidine kinetics in malignant pheochromocytoma Eur J Nucl Med 14 7-8 1988 345 348
53. T.J. Mangner, M.C. Tobes, D.W. Wieland, and et al. Metabolism of I-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma J Nucl Med 27 1 1986 37 44
54. E. Sternthal, L. Lipworth, B. Stanley, and et al. Suppression of thyroid radioiodine uptake by various doses of stable iodide N Engl J Med 303 19 1980 1083 1088
55. P.B. Zanzonico, and D.V. Becker Effects of time of administration and dietary iodine levels on potassium iodide (KI) blockade of thyroid irradiation by I-131 from radioactive fallout Health Phys 78 6 2000 660 667
56. A. Garaventa, P. Guerra, A. Arrighini, and et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine Cancer 67 4 1991 922 928
57. 131metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma J Nucl Biol Med 35 4 1991 300 304
58. G. Hor, F.D. Maul, B. Kornhuber, and et al. Outcome of [131I]metaiodobenzylguanidine therapy of neuroblastoma: Seven years after J Nucl Biol Med 35 4 1991 207 215
59. J.P. Howard, J.M. Maris, L.S. Kersun, and et al. Tumor response and toxicity with multiple infusions of high dose I-131-MIBG for refractory neuroblastoma Pediatr Blood Cancer 44 3 2005 232 239
60. L.S. Lashford, I.J. Lewis, S.L. Fielding, and et al. Phase I/II study of I-131 metaiodobenzylguanidine in chemoresistant neuroblastoma - A United Kingdom children's cancer study-group investigation J Clin Oncol 10 12 1992 1889 1896
61. G.A. Yanik, J.E. Levine, K.K. Matthay, and et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma J Clin Oncol 20 8 2002 2142 2149
62. J.L. Pasieka, A.J.B. McEwan, and O. Rorstad The palliative role of I-131-MIBG and In-111-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms Surgery 136 6 2004 1218 1226
63. C. Nguyen, M. Faraggi, A.L. Giraudet, and et al. Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy J Nucl Med 45 10 2004 1660 1668
64. B. Shapiro, J.C. Sisson, R. Lloyd, and et al. Malignant pheochromocytoma - Clinical, biochemical and scintigraphic characterization Clin Endocrinol 20 2 1984 189 203
65. B.G. Taal, C.A. Hoefnagel, R.A. Valdes-Olmos, and et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors J Clin Oncol 14 6 1996 1829 1838
66. A.A. Pathirana, S. Vinjamuri, C. Byrne, and et al. I-131-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome Eur J Surg Oncol 27 4 2001 404 408
67. M. Schlumberger, C. Gicquel, J. Lumbroso, and et al. Malignant pheochromocytoma - Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases J Endocrinol Invest 15 9 1992 631 642
68. B. Shapiro, I.C. Sisson, D.M. Wieland, and et al. Radiopharmaceutical therapy of malignant pheochromocytoma with I-131 metaiodobenzylguanidine: Results from ten years of experience J Nucl Biol Med 35 4 1991 269 276
69. J.B. Bomanji, W. Wong, M.N. Gaze, and et al. Treatment of neuroendocrine tumours in adults with I-131-MIBG therapy Clin Oncol 15 4 2003 193 198
70. C.A. Hoefnagel, F.C. den Hartog Jager, B.G. Taal, and et al. The role of I-131 metaiodobenzylguanidine in the diagnosis and therapy of carcinoids Eur J Nucl Med 13 4 1987 187 191
71. J.E. Gains, C. Walker, T.M. Sullivan, and et al. Radiation exposure to comforters and carers during paediatric molecular radiotherapy Pediatr Blood Cancer 62 2 2015 235 239
72. R.J. Markelewicz Jr., W.A. Lorenzen, S. Shusterman, and et al. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving I-131-metaiodobenzylguanidine (I-131-MIBG) therapy Clin Nucl Med 38 8 2013 604 607
73. A. Hartley, D. Spooner, and A.M. Brunt Management of malignant phaeochromocytoma: A retrospective review of the use of MIBG and chemotherapy in the West Midlands Clin Oncol 13 5 2001 361 366
74. B. Rose, K.K. Matthay, D. Price, and et al. High-dose I-131-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma Cancer 98 2 2003 239 248
75. K.K. Matthay, G. Yanik, J. Messina, and et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma J Clin Oncol 25 9 2007 1054 1060
76. S.L. Fielding, M.A. Flower, D. Ackery, and et al. Dosimetry of I-131 metaiodobenzylguanidine for treatment of resistant neuroblastoma - Results of a UK study Eur J Nucl Med 18 5 1991 308 316
77. M.N. Gaze, Y.C. Chang, G.D. Flux, and et al. Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma Cancer Biother Radiopharm 20 2 2005 195 199
78. C.-L. Lee, H. Wahnishe, G.A. Sayre, and et al. Radiation dose estimation using preclinical imaging with I-124-metaiodobenzylguanidine (MIBG) PET Med Phys 37 9 2010 4861 4867
79. K.F. Koral, X.H. Wang, J.C. Sisson, and et al. Calculating radiation absorbed dose for pheochromocytoma tumors in 131-I MIBG therapy Int J Radiat Oncol 17 1 1989 211 218
80. P. Minguez, G. Flux, J. Genolla, and et al. Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with I-131-metaiodobenzylguanidine with implications for the activity to administer Med Phys 42 7 2015 3969 3978
81. J. Bomanji, K.E. Britton, E. Ur, and et al. Treatment of malignant pheochromocytoma, paraganglioma and carcinoid-tumors with I-131 metaiodobenzylguanidine Nucl Med Commun 14 10 1993 856 861
82. J.R. Buscombe, J.B. Cwikla, M.E. Caplin, and et al. Long-term efficacy of low activity meta-[I-131]iodobenzylguanidine therapy in patients with disseminated neuroendocrine turnours depends on initial response Nucl Med Commun 26 11 2005 969 976
83. M. Krempf, J. Lumbroso, R. Mornex, and et al. Use of m-[I-131]iodobenzylguanidine in the treatment of malignant pheochromocytoma J Clin Endocrinol Metab 72 2 1991 455 461
84. R.E. Goldsby, and P.A. Fitzgerald Meta I-131 iodobenzylguanidine therapy for patients with metastatic and unresectable pheochromocytoma and paraganglionna Nucl Med Biol 35 2008 S49 S62
85. G. Ehninger, T. Klingebiel, I. Kumbier, and et al. Stability and pharmacokinetics of m-[131I]iodobenzylguanidine in patients Cancer Res 47 22 1987 6147 6149
86. L.S. Lashford, J. Moyes, R. Ott, and et al. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma Eur J Nucl Med 13 11 1988 574 577
87. A.R. Wafelman, Y.L. Nortier, H. Rosing, and et al. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance Nucl Med Commun 16 9 1995 767 772
88. A.R. Wafelman, C.A. Hoefnagel, H.J.M. Maessen, and et al. Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours Eur J Nucl Med 24 5 1997 544 552
89. 131I-metaiodobenzylguanidine (MIBG). Paper Presented At: Fourth International Radiopharmaceutical Dosimetry Symposium, 1992, Oakridge, TN
90. M. Tristam, A.S. Alaamer, J.S. Fleming, and et al. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: Risk versus benefit J Nucl Med 37 6 1996 1058 1063
91. S.E. Buckley, F.H. Saran, M.N. Gaze, and et al. Dosimetry for fractionated I-131-MIBG therapies in patients with primary resistant high-risk neuroblastoma: Preliminary results Cancer Biother Radiopharm 22 1 2007 105 112
92. L. Troncone, R. Riccardi, P. Montemaggi, and et al. Treatment of neuroblastoma with I-131 metaiodobenzylguanidine Med Pediatr Oncol 15 4 1987 220 223
93. M. Shilkrut, R. Bar-Deroma, G. Bar-Sela, and et al. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma single center experience Am J Clin Oncol-Canc 33 1 2010 79 82
94. 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma Eur J Nucl Med Mol Imaging 38 10 2011 1869 1875
95. B.G. Taal, H. Zuetenhorst, R.A. Valdes-Olmos, and et al. [I-131]MIBG radionuclide therapy in carcinoid syndrome Eur J Surg Oncol 28 3 2002 243
96. M.R. Castellani, A. Chiti, E. Seregni, and et al. Role of I-131-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours - Experience of the National Cancer Institute of Milan Q J Nucl Med 44 1 2000 77 87
97. P.A. Fitzgerald, R.E. Goldsby, J.P. Huberty, and et al. Malignant pheochromocytomas and paragangliomas - A phase II study of therapy with high-dose I-131-metaiodobenzylguanidine (I-131-MIBG), vol 1073 Pheochromocytoma 2006 Blackwell Publishing Oxford 465 490
98. S.D. Safford, E. Coleman, J.P. Gockerman, and et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma Surgery 134 6 2003 956 962
99. D.A. Pryma, R.E. Coleman, R. Noto, and et al. Interim results of an open-label, single-arm trial of ultratrace I-131-iobenguane in patients with metastatic pheochromocytoma/paraganglioma (Pheo) J Clin Oncol 30 2012 15
100. H. Wakabayashi, J. Taki, A. Inaki, and et al. Prognostic values of initial responses to low-dose I-131-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma Ann Nucl Med 27 9 2013 839 846
101. M.A. Rutherford, A.J. Rankin, T.M. Yates, and et al. Management of metastatic phaeochromocytoma and paraganglioma: Use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre QJM 108 5 2015 361 368
102. I. Jawed, L. Amiri-Kordestani, M. Velarde, and et al. High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B (SDHB) mutations J Clin Oncol 29 2011 15
103. M.E.B. Pichun, M. Edgerly, M. Velarde, and et al. Phase II clinical trial of axitinib in metastatic pheochromocytomas and paraganlgiomas (P/PG): Preliminary results J Clin Oncol 33 2015 7
104. 131I-MIBG and sunitinib induces remission in a patient with metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome from an SDHB mutation Clin Nucl Med 2015
105. E. Goncalves, J. Ninane, F.X. Wese, and et al. Familial pheochromocytoma - Successful treatment with I-131 MIBG Med Pediatr Oncol 18 2 1990 126 130
106. W.C.C. Sze, A.B. Grossman, I. Goddard, and et al. Sequelae and survivorship in patients treated with I-131-MIBG therapy Br J Cancer 109 3 2013 565 572
107. V.J. Lewington, M.A. Zivanovic, M. Tristam, and et al. Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma J Nucl Biol Med 35 4 1991 280 283
108. B. Weiss, A. Vora, J. Huberty, and et al. Secondary myelodysplastic syndrome and leukemia following I-131-metaiodobenzylguanidine therapy for relapsed neuroblastoma J Pediatr Hematol Oncol 25 7 2003 543 547
109. S. Modak, N. Pandit-Taskar, B.H. Kushner, and et al. Transient sialoadenitis: A complication of I-131-metaiodobenzylguanidine therapy Pediatr Blood Cancer 50 6 2008 1271 1273
110. A. Porzig, K.K. Matthay, S. Dubois, and et al. Proteinuria in metastatic pheochromocytoma is associated with an increased risk of acute respiratory distress syndrome, spontaneously or after therapy with I-131-meta-iodobenzylguanidine (I-131-MIBG) Horm Metab Res 44 7 2012 539 542
111. J.C. Reubi, B. Waser, S. Khosla, and et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas J Clin Endocrinol Metab 74 5 1992 1082 1089
112. J. Mundschenk, N. Unger, S. Schulz, and et al. Somatostatin receptor subtypes in human pheochromocytoma: Subcellular expression pattern and functional relevance for octreotide scintigraphy J Clin Endocrinol Metab 88 11 2003 5150 5157
113. M. van Essen, E.P. Krenning, P.P. Kooij, and et al. Effects of therapy with [Lu-177-DOTA(0),Tyr(3)] octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma J Nucl Med 47 10 2006 1599 1606
114. 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors J Nucl Med 51 10 2010 1524 1531
115. F. Forrer, I. Riedweg, H.R. Maecke, and et al. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma Q J Nucl Med Mol Imaging 52 4 2008 334 340
116. L. Kolby, P. Bernhardt, V. Johanson, and et al. Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? K Pacak, G Eisenhofer, Pheochromocytoma 1073 2006 491 497
117. B. Luzon-Toro, A. Geerlings, and S. Hilfiker Hydroxytyrosol increases norepinephrine transporter function in pheochromocytoma cells Nucl Med Biol 35 7 2008 801 804
118. L. Martiniova, S.M. Perera, F.M. Brouwers, and et al. Increased uptake of I-123 meta-iodobenzylguanidine, F-18 fluorodopamine, and H-3 norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors Endocr Relat Cancer 18 1 2011 143 157
119. S.H. Rachh, S. Abhyankar, and S. Basu I-131 Metaiodobenzylguanidine therapy in neural crest tumors: varying outcome in different histopathologies Nucl Med Commun 32 2011 1201 1210